Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 7 9 2019
medline: 7 10 2020
entrez: 7 9 2019
Statut: ppublish

Résumé

We examined the 10-year experience of Mayo Clinic's kidney paired donation (KPD).We aimed to determine the benefits for the recipients of enrolled ABO/HLA compatible pairs and determine the factors associated with prolonged KPD waiting time. We performed a retrospective study of 332 kidney transplants facilitated by the Mayo 3-site KPD program from September 2007 to June 2018. The median (interquartile range) time from KPD entry to transplantation was 89 days (42-187 days). The factors independently associated with receiving a transplant >3 months after KPD entry included recipient blood type O and calculated panel reactive antibodies ≥98%. Fifty-four ABO/HLA compatible pairs participated in KPD for the following reasons: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr virus (EBV) mismatch (EBV) (9.3% [5/54]), age/size mismatch (51.9% [28/54]), or altruistic reasons (20.3% [11/54]). Cytomegalovirus and EBV mismatch were avoided in 90% (9/10) and 100% (5/5) of cases. Recipients who entered KPD for age/size mismatch and altruistic reasons received kidneys from donors with lower Living Kidney Donor Profile Index scores than their actual donor (median [interquartile range] 31.5 [12.3-47]; P < 0.001 and 26 (-1 to 46); P = 0.01 points lower, respectively). Median time to transplant from KPD entry for compatible pair recipients was 70 days (41-163 days), and 44.4% (24/54) of these transplants were preemptive. All chains/swaps incorporating compatible pairs included ABO/HLA incompatible pairs. KPD should be considered for all living donor/recipient pairs because the recipients of these pairs can derive personal benefit from KPD while increasing the donor pool for difficult to match pairs.

Sections du résumé

BACKGROUND
We examined the 10-year experience of Mayo Clinic's kidney paired donation (KPD).We aimed to determine the benefits for the recipients of enrolled ABO/HLA compatible pairs and determine the factors associated with prolonged KPD waiting time.
METHODS
We performed a retrospective study of 332 kidney transplants facilitated by the Mayo 3-site KPD program from September 2007 to June 2018.
RESULTS
The median (interquartile range) time from KPD entry to transplantation was 89 days (42-187 days). The factors independently associated with receiving a transplant >3 months after KPD entry included recipient blood type O and calculated panel reactive antibodies ≥98%. Fifty-four ABO/HLA compatible pairs participated in KPD for the following reasons: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr virus (EBV) mismatch (EBV) (9.3% [5/54]), age/size mismatch (51.9% [28/54]), or altruistic reasons (20.3% [11/54]). Cytomegalovirus and EBV mismatch were avoided in 90% (9/10) and 100% (5/5) of cases. Recipients who entered KPD for age/size mismatch and altruistic reasons received kidneys from donors with lower Living Kidney Donor Profile Index scores than their actual donor (median [interquartile range] 31.5 [12.3-47]; P < 0.001 and 26 (-1 to 46); P = 0.01 points lower, respectively). Median time to transplant from KPD entry for compatible pair recipients was 70 days (41-163 days), and 44.4% (24/54) of these transplants were preemptive. All chains/swaps incorporating compatible pairs included ABO/HLA incompatible pairs.
CONCLUSIONS
KPD should be considered for all living donor/recipient pairs because the recipients of these pairs can derive personal benefit from KPD while increasing the donor pool for difficult to match pairs.

Identifiants

pubmed: 31490859
doi: 10.1097/TP.0000000000002947
pmc: PMC7359217
mid: NIHMS1600011
pii: 00007890-202006000-00024
doi:

Substances chimiques

ABO Blood-Group System 0
HLA Antigens 0

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1229-1238

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK123313
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002379
Pays : United States

Références

Am J Transplant. 2015 Jun;15(6):1484-9
pubmed: 25773372
Transplantation. 2017 Mar;101(3):642-648
pubmed: 27077598
Clin Transpl. 2013;:235-9
pubmed: 25095513
Nephrol Dial Transplant. 2011 Jul;26(7):2091-9
pubmed: 21454351
Int Urol Nephrol. 2014 Jul;46(7):1441-6
pubmed: 24526331
Transplant Direct. 2016 Jun 06;2(7):e85
pubmed: 27830179
Transplant Proc. 2012 Jan;44(1):270-2
pubmed: 22310630
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):669-676
pubmed: 28360198
Clin Transplant. 2013 Nov-Dec;27(6):838-43
pubmed: 23991890
Am J Transplant. 2017 Oct;17(10):2745-2746
pubmed: 28834177
Nephrol Dial Transplant. 2012 Jul;27(7):2971-9
pubmed: 22273720
Am J Transplant. 2011 Jun;11(6):1279-86
pubmed: 21564530
Am J Transplant. 2016 Jul;16(7):2077-84
pubmed: 26752290
Transplantation. 2014 Aug 15;98(3):300-5
pubmed: 24699400
Am J Transplant. 2017 Jul;17(7):1723-1728
pubmed: 28321984
Am J Transplant. 2019 Feb;19(2):573-584
pubmed: 30431703
Am J Transplant. 2012 Nov;12(11):3031-8
pubmed: 22900931
Transpl Int. 2013 May;26(5):493-501
pubmed: 23384401
Am J Transplant. 2012 Aug;12(8):2125-32
pubmed: 22548839
Clin Transplant. 2017 Jun;31(6):
pubmed: 28342273
Am J Transplant. 2018 Nov;18(11):2730-2738
pubmed: 29603640
Transplantation. 2007 Jul 27;84(2):137-43
pubmed: 17667803
Am J Transplant. 2010 Mar;10(3):449-57
pubmed: 20121749

Auteurs

Arpita Basu (A)

Department of Medicine, Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.

Mikel Prieto (M)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Catherine Kosberg (C)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Martin L Mai (ML)

Department of Medicine, Division of Transplantation, Mayo Clinic, Jacksonville, FL.

Hasan A Khamash (HA)

Department of Medicine, Division of Transplantation, Mayo Clinic, Scottsdale, AZ.

Caroline C Jadlowiec (CC)

Department of Medicine, Division of Transplantation, Mayo Clinic, Scottsdale, AZ.

Naim S Issa (NS)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Patrick G Dean (PG)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Elizabeth C Lorenz (EC)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Mark D Stegall (MD)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Carrie A Schinstock (CA)

Mayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH